Welcome to our dedicated page for Renovaro SEC filings (Ticker: RENB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Lunai Bioworks Inc. (historically trading under the symbol RENB and later LNAI on Nasdaq) provide detailed insight into the company’s corporate evolution, governance, and capital markets activity. As a Delaware corporation with common stock registered under Section 12(b) of the Securities Exchange Act of 1934, Lunai Bioworks submits periodic and current reports, proxy statements, and other disclosures that document its strategic decisions and compliance with exchange rules.
Recent Form 8-K filings capture several material events relevant to investors. An 8-K dated August 26, 2025 reports a Certificate of Amendment changing the corporate name from Renovaro Inc. to Lunai Bioworks Inc., with the name change effective August 20, 2025 while the stock continued to trade under the RENB ticker. Another 8-K filed on September 24, 2025 describes a 1-for-10 reverse stock split of the company’s common stock and notes that the shares would begin trading on a reverse-split-adjusted basis on the Nasdaq Capital Market under the symbol LNAI on September 30, 2025. These filings explain how the share count, ticker symbol, and CUSIP were adjusted.
Nasdaq listing compliance is another recurring theme in Lunai Bioworks’ filings. An 8-K dated August 6, 2025 discloses a notice of non-compliance with Nasdaq Listing Rule 5620(a) regarding the timing of the annual meeting and an extension to hold the meeting by October 31, 2025. An 8-K dated November 6, 2025 then reports that, after holding its annual meeting on October 31, 2025, Nasdaq determined that the company had regained compliance with that rule. Separate 8-K filings dated October 16, 2025 and October 30, 2025 describe, respectively, the company’s return to compliance with the minimum bid price requirement under Listing Rule 5550(a)(2) and a notice of non-compliance with the $35 million minimum market value of listed securities requirement under Listing Rule 5550(b)(2), along with a 180-day cure period.
Proxy materials also play an important role in understanding Lunai Bioworks’ governance and compensation structure. A definitive proxy statement on Schedule 14A dated October 15, 2025 outlines the agenda for the 2025 annual meeting, including the election of directors, an advisory vote on executive compensation, ratification of the independent registered public accounting firm, and proposed amendments to the company’s 2023 Equity Incentive Plan. An 8-K filed on November 3, 2025 reports the voting results, confirming that stockholders approved all four proposals.
Additional filings address the bankruptcy of an indirect subsidiary, Gedi Cube B.V., and the associated asset impairment. An 8-K dated September 5, 2025 notes that the Court of Amsterdam declared Gedi Cube B.V. bankrupt after a voluntary petition and that Lunai Bioworks and its other subsidiaries were not filing for bankruptcy protection. The filing states that management determined a material impairment had occurred and expected to record an impairment charge in its quarterly report. Together, these documents provide a regulatory record of how Lunai Bioworks manages its corporate structure, equity, and compliance obligations.
On Stock Titan’s SEC filings page, users can review these and other Lunai Bioworks disclosures in one place. AI-powered tools can help summarize lengthy documents such as proxy statements and current reports, highlight key items like reverse stock splits, name changes, listing notices, and subsidiary events, and make it easier to track how board decisions and shareholder votes shape the company’s capital structure and governance over time.
Renovaro Inc. (Nasdaq: RENB) disclosed in an 8-K that it received a Nasdaq Listing Rule 5620(a) deficiency notice on 7 July 2025 for failing to hold its FY 2024 annual shareholder meeting within 12 months of the 30 June 2024 fiscal year-end.
The company has 45 calendar days to submit a remediation plan; if Nasdaq accepts it, Renovaro could receive an extension until 29 December 2025 to regain compliance. Until then, the stock will continue trading on Nasdaq. Failure to file an acceptable plan or to hold the meeting by the deadline could lead to delisting.
Management states it is “working diligently” to prepare the plan and schedule the meeting “as soon as practicable.” No other operational or financial metrics were disclosed.